Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm, Immunexpress and Biocartis Announce Collaboration

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
Collaboration to advance development of SeptiCyte® Triage for managing sepsis.

Debiopharm Group™ (Debiopharm), Immunexpress Group and Biocartis have announced a world-wide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage - a multiplex gene expression assay for use in Emergency and Intensive Care Units (ICUs) or upon hospital admission to diagnose sepsis early, differentiate sepsis from other forms of inflammation, and determine sepsis severity.

Under the terms of the agreement, Debiopharm will fund the validation and U.S. Food and Drug Administration (FDA) clearance of SeptiCyte® Triage and Biocartis will subsequently fund the development and commercialization of the validated SeptiCyte® Triage assay on its fully integrated molecular diagnostics platform.

This platform - which includes an instrument, communication console, and single use, disposable cartridges - can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with minimal user intervention in less than 90 minutes.

As part of the agreement, Debiopharm will complete an equity investment in Immunexpress of AUD 2 million.

“The synergy created by this partnership is not only important for the continued development and future availability of SeptiCyte® Triage - but it also exemplifies Immunexpress’ commitment to innovative science and partnerships that improve outcomes for clinicians and patients”, said Dr Roslyn Brandon, President and CEO, Immunexpress.

Dr Brandon continued, “With accuracy significantly better than procalcitonin, bringing SeptiCyte® Triage onto Biocartis’ revolutionary point-of-need multiplex qRT-PCR platform will enable clinicians to more quickly and accurately identify and triage patients suspected of sepsis».

Greg Parekh, Biocartis’ CEO, commented: “Biocartis is striving to bring more effective, individualized treatments within reach of patients through the availability of high quality diagnostics at the point of need. Sepsis is a major cause of death where timely accurate diagnostic information can make a significant difference in medical outcomes”.

“Debiopharm is enthusiastic to join forces with Immunexpress and Biocartis and to take an additional step in our strong commitment to personalized medicine”, said Thierry Mauvernay, Debiopharm’s delegate of the board, who added, “The collaboration opens the door to exploit synergies between the three companies by addressing this life-threatening condition from different perspectives, particularly from a health economics one. Supporting better management of sepsis may ultimately lead to a reduction in mortality, better outcomes and possibly the discovery of new therapies”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Immunexpress Closes $6M Financing Round led by Debiopharm
Funding to advance development of the Immunexpress SeptiCyte® technology.
Thursday, March 06, 2014
Debiopharm to Acquire Affinium’s Antibiotic Clinical Assets and Platform
Company acquire clinical and preclinical assets to identify and develop targeted antibiotics.
Wednesday, February 12, 2014
Diagnoplex S.A. Closes a Financing Round Led by Debiopharm Group™
Diagnoplex secures 1.3 million Swiss francs from financing round.
Friday, June 07, 2013
Augurix Receives the 2011 ‘Debiopharm /Valais Award’
Company receives award for its point-of-care diagnostic test for the early detection of Celiac disease.
Wednesday, November 16, 2011
Debiopharm Group™ Starts Phase I Clinical Trial with Debio 0932
A targeted small molecule inhibitor of heat shock protein 90 for cancer treatment.
Wednesday, April 28, 2010
Debiopharm Group™ and Biocartis embark on a Partnership Aiming at Enhancing Personalized Medicine
- Debiopharm Group™ , a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
Thursday, April 08, 2010
Debiopharm Group™ Grants Licence for Development, Manufacture and Commercialization of Debio 025
The product is currently in phase 2b clinical development for the treatment of hepatitis C.
Wednesday, February 10, 2010
Scientific News
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!